Autoinflammatory attacks in familial Mediterranean fever (FMF) are accompanied by elevated levels of interleukin-6 (IL-6), and are controllable by IL-1-targeting drugs. In combination, IL-6 and IL-1 are known to be potent inducers of T helper (Th) 17 cells development. Therefore, we studied the Th17 population size, and activation potential, of FMF patients. Based on the relative mRNA expression of the Th1, Th2, Treg and Th17 transcription factors T-bet, GATA3, FOXP3 and retinoic acid-related orphan receptor gT (RORgT), respectively, the Th17 population in peripheral blood mononuclear cells (PBMCs) of healthy subjects was estimated at 2.5% of the entire Th population and 4.4% in FMF patients in remission (n ¼ 6 for each group, P ¼ 0.03). IL-17 secretion after universal stimulation of the T-cell receptor in PBMCs culture was twice higher in cultures of patients with frequent attacks (n ¼ 18) than in those of patients with infrequent attacks (n ¼ 10, 1124 ± 266 vs 615 ± 196 pg ml À 1 , P ¼ 0.009). IL-17 secretion correlated well with IL17A mRNA level. Part of the increased secretion was related to the deleterious, MEFV p.M694V homozygous genotype (n ¼ 19, 1.5-fold, P ¼ 0.03). Almost all IL-17 producer cells were CD4-positive (CD4 þ IL-17 þ ). In conclusion, frequent attacks and the deleterious FMF genotype appear to drive FMF patients to a heightened Th17 response.
INTRODUCTION
Familial Mediterranean fever (FMF) is an autoinflammatory recessive disease, with recurrent febrile attacks of peritonitis, pleuritis, mono-arthritis and/or erysipelas like erythema, lasting 3-5 days, and accumulation of neutrophils in the inflamed sites. Attacks are also characterized by a systemic, acute phase response.
1 Elevated interleukin-6 (IL-6) levels, implicated in the induction of the acute phase reactants, are consistently measured during attacks, and are thought to mediate the acute phase response. [2] [3] [4] IL-1b, although not readily detected in the serum of FMF patients, also appears to have a pathogenic role in FMF attacks, since drugs that target this cytokine are effective in controlling attacks in patients. 5 Indeed, pathogenic variants in the MEFV gene encoding pyrin, which are responsible for FMF in most patients, enhance the intracellular processing of IL-1 in the inflammasome to a mature secreted cytokine. 6 In combination, IL-6 and IL-1 support the development of T helper 17 (Th17) cells, a recently recognized small T-cell subset that secretes IL-17, implicated in recruiting polymorphonuclear leukocytes to inflamed sites. [7] [8] [9] [10] [11] A modest increase in IL-17 serum levels in FMF patients in remission and more so in attack has already been reported. [12] [13] [14] In this study, we estimate the size of the Th17 population in the peripheral blood mononuclear cells (PBMCs), and the amount of IL-17 secreted following activation of T cells of FMF patients in relation to disease activity and genotype, and suggest the presence of a heightened Th17 response in FMF.
RESULTS AND DISCUSSION
The size of the Th17 population in the peripheral blood was first estimated by the expression of RORgT mRNA, encoding a Th17-specific transcription factor, relatively to T-bet (Th1 specific) and GATA3 (Th2 specific) mRNAs (Table 1) . Real-time PCR revealed that T-bet and GATA3 mRNAs were about 26-and 12-fold more abundant than RORgT mRNA in freshly derived healthy PBMCs, respectively ( Table 2 ). The mRNA level of FOXP3 encoding the T regulatory cells specific transcription factor, was comparable to that of RORgT. If each Th cell expressed only one type of a transcription factor then the Th17 cells are estimated to be about 2.5% of the peripheral blood Th population and, based on relative expression of the Th transcription factors, the Th17:Th1 ratio is 0.04, and the Th17:Th2 ratio is 0.08. The only significant change found in FMF patients in remission from the detailed pattern of transcription factors was a 2.3-fold higher expression of RORgT (n ¼ 6 in each group, P ¼ 0.03, Table 2 ). If expression level is fixed per cell, then in remission of FMF patients, the Th17 cells may reach 4.4% of the T-cell population and Th17:Th1 and Th17:Th2 ratios obtained are higher (0.07 and 0.13, respectively). These may be features of Th17 polarization in FMF. In two attack samples, no change could be observed in the transcription factors mRNA levels.
IL17A, whose expression is promoted by RORgT, was not depicted in freshly derived PBMCs mRNA by qualitative real-time PCR. IL-17-positive cells were hardly detected by fluorescence-activated cell sorter analysis, and the protein was barely detected by enzyme-linked immunosorbent assay of serum, whether of healthy subjects, or FMF patients in remission or attack (n ¼ 3 in each group, Table 3 ). In the same cohort, the acute phase reactant serum amyloid A rose 60-fold in the serum of patients in attack (358 ± 218 vs 5.7 ± 1.8 and 5.7 ± 2.5 mg l À 1 in patients in attack, remission and healthy subject samples, respectively).
Activation of the freshly derived PBMCs in culture with OKT3, an anti-CD3 antibody activating the T-cell receptor (TCR), resulted in the accumulation of both IL-17 and interferon-g in the culture medium (Table 3 ). Cytokines levels in the medium of cultures not exposed to OKT3 were very low (data not shown). Although on day 3 of culture, IL-17 concentrations ranged widely, the average IL-17 concentration was elevated 1.24-fold in FMF attack samples over FMF remission samples and 1.4-fold over healthy subjects samples showing a trend to statistical significance.
Irrespective of attack or remission status, stimulated PBMCs derived from p.M694V homozygous FMF patients (n ¼ 19) secreted in average 1.5-fold more IL-17 than those of the other MEFV genotypes group (n ¼ 9), over 3 days of culture (P ¼ 0.029, Table 3, Figure 1 ). Moreover, PBMCs of patients with uncontrolled disease (n ¼ 18) secreted twofold more IL-17 than those with controlled disease (n ¼ 10, P ¼ 0.009, Table 3 and Figure 1 ). Analysis of variance showed that the genotype and disease activity contributed independently and additively to IL-17 levels, but not to interferon-g culture medium levels. However, interferon-g was analyzed on a smaller sample size.
TCR stimulation by OKT3 induced IL17 mRNA de novo, and its level, on day 3 of culture of both FMF patients and healthy subjects correlated well to the amount of IL-17 secreted per culture ( Figure 2 , R 2 ¼ 0.567), indicating that about half of the variation in IL-17 concentration is related to its transcriptional level.
Direct count of IL-17-positive cells in TCR stimulated PBMCs, cultured 1-6 days, fluctuated between 0.3 and 1% of healthy lymphocytes (Figure 3a) . In all, 1.1% of the lymphocytes of an FMF patient in remission, cultured for 4 days, stained IL-17 positive, and almost all were double stained with the Th accessory cell surface molecule CD4 (Figure 3b ). The highest IL-17 cells fraction was found in a culture of an FMF patient in attack, on day 5 of culture RQb-FMF patients, relative mRNA quantity of each transcription factor compared with its own expression in healthy subjects. Figure 3c ). A sister culture supplemented by the IL-17 cells expansion factor IL-23 and harvested on day 4, had twice more IL-17 þ cells (4.8%, Figure 3d ). Taken together, our data demonstrate a small pool of RORgTexpressing cells in the freshly derived PBMCs that secreted IL-17 on TCR stimulation. This pool is either modestly enlarged or more responsive to TCR stimulation in FMF patients homozygous for the p.M694V variant of the Mediterranean fever gene and/or with active disease.
We report here on the impact of FMF, a disorder of the innate immune system, on four parameters indicating on the status and function of Th17 cells in peripheral blood: a modest increase in expression of the specific transcription factor of the Th17 lineage, RORgT, higher than the normal secretion of IL-17 following TCR activation and predisposition by both active disease and carriage of the p.M694V homozygous MEFV genotype, usually underling a severe phenotype of FMF. 15 The latter parameters were effective whether samples were derived from patients in attack or the remission period, and whether the patients received colchicine or not (see description of patients' subgroups in the Patients and methods section). Although Th (CD4 þ ) cells are the main source of IL-17 in PBMCs, pathologic and minute sources include other T-cell populations such as CD8 T cells, gd T cells and lymphoid tissue inducer cells. 16, 17 The source of the IL-17 in all above experiments seems to be Th17 cells, as an analysis of the activated cultures cells by fluorescence-activated cell sorter revealed that almost all of IL-17-positive cells double stained with CD4, implying Th identity of most IL-17-producing cells.
Concomitant to our work, an association between Th17 cells and autoinflammation was demonstrated in knock-in mouse models of the autoinflammatory human disease cryopyrinassociated periodic syndrome. [18] [19] [20] In one model, inserting a pathogenic NLRP3 gene variant resulted in hyper activation of the inflammasome and a Th17 cell-dominant immunopathology. 19 In the other model, bone marrow-derived dendritic cells were shown to elicit an IL-17 response, when co-cultured with naive T cells exposed to ovalbumin. 20 Finally, IL-1-targeted therapy in cryopyrin-associated periodic syndrome patients, known to cause remission, also reduced the IL-17 serum levels, reiterating the connection between autoinflammation and the heightened Th17 response. 21 The role of the predisposition to heightened Th17 response in the peripheral blood of FMF patients (and cryopyrin-associated periodic syndrome) is unknown. However, based on this study one may speculate that in FMF patients with active disease the immune response is indeed Th17 directed by the cytokine mesh that characterizes FMF. Consequently, the Th17 cells that outlive the span of the FMF attack may serve to maintain a low-grade inflammation, by recruiting neutrophils to their locality. This may be more significant in peripheral sites where Th17 cells are more abundant, such as the skin, where it may offer immunologic advantage by conferring improved resistance against organisms included in the spectrum of Th17 specificities such as certain fungi and bacteria. 22, 23 The Th17 polarization driven by pathogenic pyrin variants may explain the increased severity of several autoimmune and inflammatory diseases when the affected patients also carry a pathogenic MEFV variant, as shown in multiple sclerosis and rheumatoid arthritis. [24] [25] [26] In these disease entities, the Th17 cells were shown to have a pathogenic role, which may well be driven by both the disease-specific immunological abnormality and the MEFV-related genetic defect. 27 Indeed, regulation of intratechal inflammation in multiple sclerosis by innate cells of lymphoid tissue inducer cell type expressing RORgT was recently shown. 17 In conclusion, we demonstrate a polarization in Th17 cell activity associated with FMF, as consequence of the primary defect in pyrin and of disease activity. This immunological skew may aggravate FMF attacks but may also strengthen Th17-driven defense pathways against pathogen threats. Stimulation of T-cell cultures of FMF patients by specific Th17 stimulatory pathogens and study of IL-17-based therapy in FMF and autoinflammation are future research directions.
PATIENTS AND METHODS

Recruitment of FMF patients and healthy control subjects
Thirty-six patients at the ages of 18-50 years, diagnosed according to accepted criteria 28 were recruited, either in attack, from the medical wards or from the department of emergency medicine at the Sheba Medical Center, or in remission, from the FMF clinic on their follow-up visit. At blood donation, attack (12 patients) and remission states (24 patients) were determined by a physician expert in FMF. A questionnaire, detailing current and previous symptoms, attacks frequency, medications, background diseases and MEFV genotype was completed for all patients. Age-matched healthy subjects (n ¼ 25) were recruited from the hospital staff. The study was approved by the ethical committee of the medical center. Participants were informed on its goal, risk and procedures, 
Another subdivision of the samples of the same patients was based on attack frequency, reported by the patients and in the medical files. An active disease subgroup consisted of patients who experienced their last attack less than a month before blood donation, and suffered at least four attacks per year. These were either newly diagnosed or with uncontrolled disease despite medication (n ¼ 18, 8 during attack). The second subgroup, with better controlled FMF, included 10 attack-free patients or those who had a history of at most 2 attacks per year and more than a month before donation, whether treated with colchicine or not.
PBMCs isolation, culture stimulation and harvest PBMCs were separated from 5 ml portions of anti-coagulated blood, by loading onto a 3 ml layer of lymphoprep (Axis-Shield Poc AS, Oslo, Norway) and density gradient centrifugation. A total of 1-2 million cells were recovered from 1 ml of peripheral blood.
For culture, mono-nucleated cell pellets were suspended with 1 ml of Roswell Park Memorial Institute (RPMI)-1640 medium, containing 10% fetal calf serum (HyClone Laboratories, Logan, UT, USA). Aliquots of two million cells were seeded in wells of 24-well plates, with 1.5 ml of RPMI culture medium in each well, and re-fed with fresh medium on day 4 of culture. On seeding, T cells were stimulated with murine monoclonal antibody containing hybridoma supernatant targeting CD3 (OKT3) at a 1:100 dilution (approximately 10 mg ml À 1 , a gift from Dr I Goldstein). Sister cultures were also supplemented with IL-23 (40 ng ml À 1 ). Cells and medium were collected on days 1-6, for cytokine measurement, cellstaining or RNA preparation.
Double staining of CD4
þ IL-17 þ cells
Freshly derived, or cultured OKT3-stimulated PBMCs were stimulated in phosphate-buffered saline (2 million cells per 1.5 ml) 5 h with phorbol 12-myristate 13-acetate (PMA, a protein kinase C activator, 50 ng ml À 1 ) and ionomycin (a calcium ionophore, 40 ng ml), in the presence of monensin (a Golgi apparatus blocker, 2 mg ml À 1 , all from Sigma-Aldrich, St Louis, MO, USA). The cells were then harvested by centrifugation at 1400 r.p.m. and suspended in 100 ml phosphate-buffered saline. Staining of CD3-or CD4-positive cells was done with 7 ml fluorescein isothiocyanate anti-human CD4 or CD3 antibody (eBioscience, San Diego, CA, USA) for 15 min in the dark, before IL-17 staining, followed by two phosphatebuffered saline washes and centrifugation at 2500 r.p.m. in an Eppendorf tube. For IL-17 staining, fresh or surface-stained cells were permeabilized and fixed with the FIX and PERM kit (Invitrogen, San Diego, CA, USA), according to the manufacturers' protocol and stained with PERCP-Cy5.5 conjugated anti-human IL-17A antibody (4 mg, eBioscience). Finally, the cells were washed twice in phosphate-buffered saline) and suspended in 0.5 ml of CellFIX (BD Biosciences, San Jose, CA, USA) for analysis by the fluorescence-activated cell sorter (BD FACScalibur, BD Biosciences).
Real-time PCR
Harvested cell pellets were suspended in lysis buffer with 0.01% tris (2-carboxyethyl)phosphine and frozen at À 80 1C. RNA in cell pellets was prepared with the PerfectPure RNA kit (5 PRIME, Hamburg, Germany). Complementary DNA was reverse transcribed using a kit (high capacity RNA to complementary DNA kit, Applied Biosystems, Foster City, CA, USA). Complementary DNA fragments of 75-106 bases (20 ng per reaction) were Th17 polarization in FMF A Ovadia et al amplified using gene-specific oligonucleotide primers ( 29 Relative expression of target gene compared with that in a selected sample (calibration sample) was calculated by the 2 À DDCt method. 30 Measurement of cytokines in the serum and medium by enzyme-linked immunosorbent assay
Serum from 5 ml of freshly coagulated blood, and culture medium of 2 million PBMCs were separated by centrifugation at 2500 and 1500 r.p.m. respectively for 4 min and aliquots were frozen at À 80 1C. Cytokine concentrations were determined by sandwich enzyme-linked immunosorbent assay, using the following commercial kits and according to the manufacturer's instructions: IL-17A with Quantikine kit (R&D Systems, Minneapolis, MN, USA); IL-17, interferon-g, with mini enzyme-linked immunosorbent assay development kits (Preprotech, London, UK).
Serum amyloid A serum concentration
Serum amyloid A was determined using the SAA N Latex kit (Siemens Healthcare Diagnostics, Tarrytown, NY, USA) in a Siemens Dade Behring BN II Nephelometer.
Statistical analysis
The mean and variance of grouped cytokine concentrations were compared between groups and analyzed for significant differences (Po0.05, two sided) using the Student's t-test. Significance and independence of factors affecting the secretion level of IL-17 in culture were analyzed using the analysis of variance test. The linear correlation between IL-17 protein and mRNA was described by the correlation coefficient R 2 .
